-
1
-
-
34547122001
-
The 2007 WHO classification of tumours of the central nervous system
-
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
-
(2007)
Acta Neuropathol
, vol.114
, Issue.2
, pp. 97-109
-
-
Louis, D.N.1
Ohgaki, H.2
Wiestler, O.D.3
-
2
-
-
56749156414
-
Analysis of the IDH1 codon 132 mutation in brain tumors
-
Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597-602.
-
(2008)
Acta Neuropathol
, vol.116
, Issue.6
, pp. 597-602
-
-
Balss, J.1
Meyer, J.2
Mueller, W.3
-
3
-
-
60849115270
-
IDH1 and IDH2 mutations in gliomas
-
Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
-
(2009)
N Engl J Med
, vol.360
, Issue.8
, pp. 765-773
-
-
Yan, H.1
Parsons, D.W.2
Jin, G.3
-
4
-
-
52949127312
-
An integrated genomic analysis of human glioblastoma multiforme
-
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-1812.
-
(2008)
Science
, vol.321
, Issue.5897
, pp. 1807-1812
-
-
Parsons, D.W.1
Jones, S.2
Zhang, X.3
-
5
-
-
65349150503
-
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
-
Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149-1153.
-
(2009)
Am J Pathol
, vol.174
, Issue.4
, pp. 1149-1153
-
-
Watanabe, T.1
Nobusawa, S.2
Kleihues, P.3
-
6
-
-
73649088347
-
Mutant metabolic enzymes are at the origin of gliomas
-
Yan H, Bigner DD, Velculescu V, et al. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. 2009;69(24):9157-9159.
-
(2009)
Cancer Res
, vol.69
, Issue.24
, pp. 9157-9159
-
-
Yan, H.1
Bigner, D.D.2
Velculescu, V.3
-
7
-
-
70449711757
-
Genetic alterations and signaling pathways in the evolution of gliomas
-
Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100(12):2235-2241.
-
(2009)
Cancer Sci
, vol.100
, Issue.12
, pp. 2235-2241
-
-
Ohgaki, H.1
Kleihues, P.2
-
8
-
-
68349116524
-
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
-
Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341-347.
-
(2009)
Neuro Oncol
, vol.11
, Issue.4
, pp. 341-347
-
-
Ichimura, K.1
Pearson, D.M.2
Kocialkowski, S.3
-
9
-
-
84859712831
-
Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients
-
Mukasa A, Takayanagi S, Saito K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 2012;103(3):587-592.
-
(2012)
Cancer Sci
, vol.103
, Issue.3
, pp. 587-592
-
-
Mukasa, A.1
Takayanagi, S.2
Saito, K.3
-
10
-
-
84879540566
-
IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas
-
Shibahara I, Sonoda Y, Kanamori M, et al. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol. 2012;17(6):551-561.
-
(2012)
Int J Clin Oncol
, vol.17
, Issue.6
, pp. 551-561
-
-
Shibahara, I.1
Sonoda, Y.2
Kanamori, M.3
-
11
-
-
77649122144
-
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
-
van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16(5):1597-1604.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.5
, pp. 1597-1604
-
-
Van Den Bent, M.J.1
Dubbink, H.J.2
Marie, Y.3
-
12
-
-
80052712328
-
New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status
-
Shibahara I, Sonoda Y, Kanamori M, et al. New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. Brain Tumor Pathol. 2011;28(3):203-208.
-
(2011)
Brain Tumor Pathol
, vol.28
, Issue.3
, pp. 203-208
-
-
Shibahara, I.1
Sonoda, Y.2
Kanamori, M.3
-
13
-
-
78651082266
-
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas
-
Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718.
-
(2010)
Acta Neuropathol
, vol.120
, Issue.6
, pp. 707-718
-
-
Hartmann, C.1
Hentschel, B.2
Wick, W.3
-
14
-
-
0141842674
-
Identification of a cancer stem cell in human brain tumors
-
Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18): 5821-5828.
-
(2003)
Cancer Res
, vol.63
, Issue.18
, pp. 5821-5828
-
-
Singh, S.K.1
Clarke, I.D.2
Terasaki, M.3
-
15
-
-
9244241576
-
Identification of human brain tumour initiating cells
-
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401.
-
(2004)
Nature
, vol.432
, Issue.7015
, pp. 396-401
-
-
Singh, S.K.1
Hawkins, C.2
Clarke, I.D.3
-
16
-
-
0035499267
-
Stem cells, cancer, and cancer stem cells
-
Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.
-
(2001)
Nature
, vol.414
, Issue.6859
, pp. 105-111
-
-
Reya, T.1
Morrison, S.J.2
Clarke, M.F.3
-
17
-
-
34247212827
-
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
-
Schmitz M, Temme A, Senner V, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer. 2007;96(8):1293-1301.
-
(2007)
Br J Cancer
, vol.96
, Issue.8
, pp. 1293-1301
-
-
Schmitz, M.1
Temme, A.2
Senner, V.3
-
18
-
-
84865208822
-
Nestin expression in brain tumors: Its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas
-
Arai H, Ikota H, Sugawara K, et al. Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol. 2012; 29(3):160-167.
-
(2012)
Brain Tumor Pathol
, vol.29
, Issue.3
, pp. 160-167
-
-
Arai, H.1
Ikota, H.2
Sugawara, K.3
-
19
-
-
79952119592
-
A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations
-
Yan X, Ma L, Yi D, et al. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc NatlAcad Sci USA. 2011;108(4):1591-1596.
-
(2011)
Proc NatlAcad Sci USA
, vol.108
, Issue.4
, pp. 1591-1596
-
-
Yan, X.1
Ma, L.2
Yi, D.3
-
20
-
-
40749155451
-
Stem cell marker CD133 affects clinical outcome in glioma patients
-
Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008; 14(1):123-129.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.1
, pp. 123-129
-
-
Zeppernick, F.1
Ahmadi, R.2
Campos, B.3
-
21
-
-
84883186250
-
The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence
-
Shibahara I, Sonoda Y, Saito R, et al. The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol. 2013;15(9):1151-1159.
-
(2013)
Neuro Oncol
, vol.15
, Issue.9
, pp. 1151-1159
-
-
Shibahara, I.1
Sonoda, Y.2
Saito, R.3
-
22
-
-
77949653208
-
Association of stem cell marker CD133 expression with dissemination of glioblastomas
-
Sato A, Sakurada K, Kumabe T, et al. Association of stem cell marker CD133 expression with dissemination of glioblastomas. Neurosurg Rev. 2010;33(2):175-183.
-
(2010)
Neurosurg Rev
, vol.33
, Issue.2
, pp. 175-183
-
-
Sato, A.1
Sakurada, K.2
Kumabe, T.3
-
23
-
-
72149119461
-
Presence of pluripotent CD133+ cells correlates with malignancy of gliomas
-
Thon N, Damianoff K, Hegermann J, et al. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol Cell Neurosci. 2010;43(1):51-59.
-
(2010)
Mol Cell Neurosci
, vol.43
, Issue.1
, pp. 51-59
-
-
Thon, N.1
Damianoff, K.2
Hegermann, J.3
-
24
-
-
60149107175
-
Nestin and CD133: Valuable stem cell-specific markers for determining clinical outcome of glioma patients
-
Zhang M, Song T, Yang L, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res. 2008;27:85.
-
(2008)
J Exp Clin Cancer Res
, vol.27
, pp. 85
-
-
Zhang, M.1
Song, T.2
Yang, L.3
-
25
-
-
79956363309
-
SOX2 expression and amplification in gliomas and glioma cell lines
-
Annovazzi L, Mellai M, Caldera V, et al. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics & Proteomics. 2011;8(3):139-147.
-
(2011)
Cancer Genomics & Proteomics
, vol.8
, Issue.3
, pp. 139-147
-
-
Annovazzi, L.1
Mellai, M.2
Caldera, V.3
-
26
-
-
84876176586
-
Differential expression of ID4 and its association with TP53 mutation, SOX2, SOX4 and OCT-4 expression levels
-
Galatro TF, Uno M, Oba-Shinjo SM, et al. Differential expression of ID4 and its association with TP53 mutation, SOX2, SOX4 and OCT-4 expression levels. PloS One. 2013;8(4):e61605.
-
(2013)
PloS One
, vol.8
, Issue.4
, pp. e61605
-
-
Galatro, T.F.1
Uno, M.2
Oba-Shinjo, S.M.3
-
27
-
-
34447625239
-
Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: Correlation of nestin with prognosis of patient survival
-
Strojnik T, Rosland GV, Sakariassen PO, et al. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol. 2007;68(2):133-143.
-
(2007)
Surg Neurol
, vol.68
, Issue.2
, pp. 133-143
-
-
Strojnik, T.1
Rosland, G.V.2
Sakariassen, P.O.3
-
28
-
-
79951486845
-
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
-
Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011;76(5):432-437.
-
(2011)
Neurology
, vol.76
, Issue.5
, pp. 432-437
-
-
Pope, W.B.1
Xia, Q.2
Paton, V.E.3
-
29
-
-
78651322039
-
Radiographic patterns of relapse in glioblastoma
-
Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol. 2011;101(2):319-323.
-
(2011)
J Neurooncol
, vol.101
, Issue.2
, pp. 319-323
-
-
Chamberlain, M.C.1
-
30
-
-
70449521966
-
Long-term survivors of glioblastoma: Clinical features and molecular analysis
-
Sonoda Y, Kumabe T, Watanabe M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien). 2009;151(11):1349-1358.
-
(2009)
Acta Neurochir (Wien)
, vol.151
, Issue.11
, pp. 1349-1358
-
-
Sonoda, Y.1
Kumabe, T.2
Watanabe, M.3
-
31
-
-
70349594347
-
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
-
Sonoda Y, Kumabe T, Nakamura T, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009;100(10): 1996-1998.
-
(2009)
Cancer Sci
, vol.100
, Issue.10
, pp. 1996-1998
-
-
Sonoda, Y.1
Kumabe, T.2
Nakamura, T.3
-
32
-
-
77955716591
-
O (6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma
-
Sonoda Y, Yokosawa M, Saito R, et al. O (6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol. 2010;15(4):352-358.
-
(2010)
Int J Clin Oncol
, vol.15
, Issue.4
, pp. 352-358
-
-
Sonoda, Y.1
Yokosawa, M.2
Saito, R.3
-
33
-
-
48749114753
-
Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas
-
Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 2008;88(8):808-815.
-
(2008)
Lab Invest
, vol.88
, Issue.8
, pp. 808-815
-
-
Joo, K.M.1
Kim, S.Y.2
Jin, X.3
-
34
-
-
80052709582
-
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: A prospective patient cohort at a single institution
-
Metellus P, Nanni-Metellus I, Delfino C, et al. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol. 2011;18(10):2937-2945.
-
(2011)
Ann Surg Oncol
, vol.18
, Issue.10
, pp. 2937-2945
-
-
Metellus, P.1
Nanni-Metellus, I.2
Delfino, C.3
-
35
-
-
58149456505
-
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
-
Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329-336.
-
(2009)
J Neurooncol
, vol.91
, Issue.3
, pp. 329-336
-
-
Zuniga, R.M.1
Torcuator, R.2
Jain, R.3
-
36
-
-
62449258056
-
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status
-
Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol. 2009;27(8): 1275-1279.
-
(2009)
J Clin Oncol
, vol.27
, Issue.8
, pp. 1275-1279
-
-
Brandes, A.A.1
Tosoni, A.2
Franceschi, E.3
-
37
-
-
77956227086
-
Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinicians perspective
-
van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinicians perspective. Acta Neuropathol. 2010;120(3):297-304.
-
(2010)
Acta Neuropathol
, vol.120
, Issue.3
, pp. 297-304
-
-
Van Den Bent, M.J.1
-
38
-
-
33845317573
-
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
-
Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.
-
(2006)
Nature
, vol.444
, Issue.7120
, pp. 756-760
-
-
Bao, S.1
Wu, Q.2
McLendon, R.E.3
-
39
-
-
46449115281
-
Stem cell-related self-renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
-
Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related self-renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26(18): 3015-3024.
-
(2008)
J Clin Oncol
, vol.26
, Issue.18
, pp. 3015-3024
-
-
Murat, A.1
Migliavacca, E.2
Gorlia, T.3
-
40
-
-
44649137314
-
CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors
-
Beier D, Wischhusen J, Dietmaier W, et al. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol. 2008;18(3):370-377.
-
(2008)
Brain Pathol
, vol.18
, Issue.3
, pp. 370-377
-
-
Beier, D.1
Wischhusen, J.2
Dietmaier, W.3
-
41
-
-
84857065790
-
Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR
-
Yoshimoto K, Ma X, Guan Y, et al. Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. Brain Tumor Pathol. 2011;28(4):291-296.
-
(2011)
Brain Tumor Pathol
, vol.28
, Issue.4
, pp. 291-296
-
-
Yoshimoto, K.1
Ma, X.2
Guan, Y.3
-
42
-
-
78650705036
-
Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis
-
Pallini R, Ricci-Vitiani L, Montano N, et al. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer. 2011;117(1):162-174.
-
(2011)
Cancer
, vol.117
, Issue.1
, pp. 162-174
-
-
Pallini, R.1
Ricci-Vitiani, L.2
Montano, N.3
-
43
-
-
34249332411
-
CD133(+) and CD133(2) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
-
Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(2) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67(9): 4010-4015.
-
(2007)
Cancer Res
, vol.67
, Issue.9
, pp. 4010-4015
-
-
Beier, D.1
Hau, P.2
Proescholdt, M.3
|